Guardant Health
Guardant Health's Overview
Guardant Health is a leading precision oncology company dedicated to conquering cancer through its proprietary blood tests, vast data sets, and advanced analytics. The company's flagship products, including Guardant360®, Guardant360 CDx, and Guardant Reveal™, are liquid biopsy tests used by oncologists to inform treatment decisions for patients with advanced-stage cancer. Guardant Health is also at the forefront of developing tests for early cancer detection (like the Shield™ test for colorectal cancer), recurrence monitoring, and assessing treatment response. Their core mission is to transform cancer care by providing comprehensive genomic insights to physicians and researchers, ultimately improving patient outcomes through non-invasive diagnostic solutions.
Where is Guardant Health's Headquarters?
HQ Function
The Palo Alto headquarters serves as the primary center for Guardant Health's executive leadership, research and development, corporate administration, and strategic operations, driving the company's innovation in cancer diagnostics.
Notable Features:
The facility houses state-of-the-art CLIA-certified and CAP-accredited laboratories, advanced research facilities, and modern, collaborative workspaces designed to foster scientific breakthroughs and teamwork.
Work Culture:
Guardant Health's headquarters fosters a dynamic, mission-driven work culture characterized by a strong emphasis on scientific rigor, innovation, collaboration, and a patient-first mindset. Employees are often driven by the impact of their work on cancer patients' lives.
HQ Significance:
Its location in Silicon Valley provides Guardant Health with access to a rich talent pool, cutting-edge technology, and a vibrant biotech community, crucial for its pioneering work in liquid biopsy and cancer genomics.
Values Reflected in HQ: The headquarters embodies Guardant Health's core values of patient-centricity, innovation, scientific excellence, and a relentless pursuit of conquering cancer through data and advanced diagnostics.
Location:
Guardant Health maintains a robust global presence to support oncology care worldwide. This includes international offices and strategic partnerships that facilitate clinical trial operations, commercial distribution of its diagnostic tests, research and development collaborations, and regulatory engagement in key markets across North America, Europe, Asia (including Japan and AMEA region), and other territories. This global network is crucial for making their innovative cancer detection technologies accessible to patients globally.
Street Address:
3100 E Bayshore Road
City:
Palo Alto
State/Province:
CA
Country:
USA
Guardant Health's Global Presence
Redwood City, CA, USA
Address: 505 Penobscot Dr, Redwood City, CA 94063, USA
Contributes to Guardant Health's substantial R&D and operational presence within the San Francisco Bay Area's prominent biotech cluster.
San Diego, CA, USA
Address: 10525 Vista Sorrento Pkwy, Suite 200, San Diego, CA 92121, USA
Functions as a vital center for processing patient samples and delivering actionable genomic test results to oncologists and patients across the United States.
Tokyo, Japan
Address: Level 20, Marunouchi Trust Tower Main, 1-8-3 Marunouchi, Chiyoda-ku, Tokyo 100-0005, Japan
Leads efforts for market access, adoption, and expansion of Guardant Health's liquid biopsy solutions in the Japanese oncology market and supports regional initiatives.
Epalinges, Switzerland
Address: Biopôle, Route de la Corniche 3, 1066 Epalinges, Switzerland
Spearheads the company's growth and makes its advanced cancer diagnostics accessible across diverse international healthcare systems and regulatory landscapes.
Buying Intent Signals for Guardant Health
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Guardant Health
As of April 2025, Guardant Health' leadership includes:
Investors of Guardant Health
Guardant Health has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
In the past 12 months (May 2023 - May 2024), Guardant Health experienced a notable leadership evolution with Co-founder Helmy Eltoukhy transitioning from Co-CEO to Chairman of the Board, and Co-founder AmirAli Talasaz assuming the role of sole CEO, effective January 2024. No other major C-suite hires from outside the company or departures from the executive team have been prominently announced during this period.
Departures
New Appointments:
Technology (Tech Stack) used by Guardant Health
Discover the tools Guardant Health uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Guardant Health Email Formats and Examples
Guardant Health commonly uses an email format that combines the employee's first initial with their last name. While other formats may exist within the organization, this is the most frequently observed pattern.
flast@guardanthealth.com
Format
jdoe@guardanthealth.com
Example
85%
Success rate
News and media
Guardant Health Press Release (via Business Wire) • May 7, 2024
Guardant Health Launches Shield™ LDT Blood Test for Colorectal Cancer Screening in Eligible Individuals
Guardant Health announced the U.S. launch of Shield™ LDT, its blood-based test for detecting colorectal cancer (CRC) in average-risk adults. This laboratory developed test (LDT) offers a new, convenient option for CRC screening for individuals who meet eligibility criteria....more
Guardant Health Press Release (via Business Wire) • May 7, 2024
Guardant Health Reports First Quarter 2024 Financial Results
Guardant Health released its financial results for the first quarter ended March 31, 2024. The company reported significant revenue growth, primarily driven by increased volumes in clinical and biopharmaceutical testing, and provided updates on its product pipeline and commercial strategies....more
Guardant Health Press Release (via Business Wire) • March 28, 2024
FDA Advisory Committee Votes in Favor of Guardant Health’s Shield™ Blood Test for Colorectal Cancer Screening
An advisory committee to the U.S. Food and Drug Administration (FDA) voted favorably on the benefit-risk profile of Guardant Health's Shield™ blood test for colorectal cancer screening in average-risk individuals. This marked a significant positive step towards potential FDA approval for the PMA (Premarket Approval) version of the test....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Guardant Health, are just a search away.